<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of severe asthma in adolescents and adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of severe asthma in adolescents and adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of severe asthma in adolescents and adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally Wenzel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monica Kraft, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Severe asthma afflicts 5 to 10 percent of the asthma population, but drives the majority of the morbidity and costs of the disease [<a href="#rid1">1</a>]. The clinician must first determine that a patient with severe and/or frequent respiratory symptoms suggestive of severe asthma has been given the correct diagnosis. Alternative possibilities include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma that is exacerbated by uncontrolled triggers</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma that is poorly controlled because of nonadherence</p><p class="bulletIndent1"><span class="glyph">●</span>An alternative disorder/disease that mimics asthma</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma that is exacerbated by a comorbid condition</p><p></p><p>This topic review will address the approach to a patient with symptoms suggestive of severe asthma. The general approach to asthma diagnosis and treatment and a discussion of asthma phenotypes and their influence on treatment are provided separately. (See  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>We reserve the classification of "severe asthma" for patients who require high-dose inhaled or near continuous oral glucocorticoid treatment to maintain asthma control or who never achieve control despite that treatment. The European Respiratory Society and the American Thoracic Society definition of severe asthma requires that patients have needed therapy with high-dose inhaled glucocorticoid  (<a class="graphic graphic_table graphicRef78011" href="/z/d/graphic/78011.html" rel="external">table 1</a>) and a second controller such as a long-acting beta-agonist (LABA) or leukotriene modifier/<a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> for the previous year and/or have needed systemic glucocorticoids for 50 percent or more of the year to prevent asthma from becoming uncontrolled, or which doesn’t achieve control despite this therapy  (<a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">table 2</a>) [<a href="#rid2">2</a>], despite having seen a specialist for three months or more. Other conditions must have been evaluated and excluded; potential exacerbating factors remediated; and lack of adherence determined not to be a significant contributor to poor asthma control.</p><p>The 2007 NAEPP guidelines include a category of "severe asthma" among patients who are not initially on controller medication  (<a class="graphic graphic_table graphicRef58247" href="/z/d/graphic/58247.html" rel="external">table 3</a>) [<a href="#rid3">3</a>]. Some patients who are in this category before therapy are able to achieve asthma control with moderate doses of inhaled glucocorticoids and thus do not meet criteria for severe persistent asthma. In patients with severe persistent asthma, attempts at lowering the glucocorticoid dose lead to deterioration in asthma control  (<a class="graphic graphic_table graphicRef65972" href="/z/d/graphic/65972.html" rel="external">table 4</a>) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H111922634"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Little is known about the epidemiology of severe asthma [<a href="#rid4">4</a>]. It may progress from childhood asthma, have been severe throughout life, or develop de novo in adulthood [<a href="#rid5">5-7</a>]. It is estimated that 5 to 10 percent of patients with asthma have severe asthma [<a href="#rid8">8</a>]. Native Americans may have a particularly high risk of having severe asthma; one large prospective cohort study found that among the 6 percent of patients who had clinician-diagnosed asthma, 52 percent had severe asthma (with a mean forced expiratory volume in one second [FEV<sub>1</sub>] of 61 percent of predicted) [<a href="#rid9">9</a>].</p><p>As a group, patients with severe asthma are at significant risk for work disability. The prevalence of full work disability was 14 percent in a prospective cohort study of 865 American patients with severe asthma and partial work disability was present in 38 percent [<a href="#rid10">10</a>]. However, the risk factors for the development of severe asthma, either adult or childhood onset, remain poorly understood.</p><p>Severe asthma may be more common in adult women [<a href="#rid11">11</a>]. However, women with severe asthma generally have more favorable objective findings than men, such as a better FEV<sub>1</sub> and FEV<sub>1</sub>/FVC, and lower total and specific IgE and fraction of exhaled nitric oxide (FE<sub>NO</sub>). Obesity is a risk factor for asthma.</p><p class="headingAnchor" id="H3"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>When evaluating a patient with symptoms suggestive of severe asthma, the key factors to identify are those that differentiate asthma from its mimics and those that increase the risk of exacerbations. As with less severe asthma, information about uncontrolled triggers, barriers to adherence, and contributing comorbidities should be sought [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H4"><span class="h2">History and physical</span><span class="headingEndMark"> — </span>Important elements of the history in patients with severe asthma are reviewed here. The history and physical examination findings that are typical of asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Characterize the specific symptoms (eg, dyspnea, cough, wheeze, chest tightness, sputum), their frequency and severity. Symptoms that may suggest a nonasthma diagnosis include hoarseness, prominent sputum production, constitutional symptoms, and lack of improvement with appropriate asthma medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clarify when symptoms began: childhood onset of symptoms favors a diagnosis of atopic asthma. Asthma is diagnosed in childhood in approximately 75 percent of all asthma patients; however, adult-onset asthma tends to be more severe and less likely allergic [<a href="#rid13">13</a>]. When Type-2 inflammation is also present, it may predict response to anti-interleukin (IL)-5 pathway therapies [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify temporal patterns of symptoms: nocturnal symptoms suggest greater asthma severity, although gastroesophageal reflux disease (GERD) and obstructive sleep apnea may also cause nocturnal choking and dyspnea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determine the severity of exacerbations: previous emergency department visits, hospitalizations, and/or invasive mechanical ventilation imply a greater risk of future severe asthma exacerbations.</p><p></p><p>Women frequently describe greater allergic (and general) symptoms, have lower asthma-specific quality of life, are more likely to be obese, and have more frequent and severe exacerbations [<a href="#rid11">11</a>]. Women with premenstrual asthma appear to be at a particularly high risk of severe asthma exacerbations [<a href="#rid15">15</a>]. While the reasons for more symptomatic disease in women as compared with men remain unknown, it is important to consider severe asthma in women despite lesser (but not absent) objective findings [<a href="#rid15">15</a>].</p><p>Additional helpful questions include whether asthma symptoms vary with the menstrual cycle [<a href="#rid16">16</a>]; whether symptoms began after an upper respiratory infection (may suggest bronchiolitis); and if the patient has had pneumonia or recurrent bronchitis (may suggest bronchiectasis).</p><p>The physical examination should include a thorough nasal/sinus evaluation, looking for stigmata of nasal obstruction, nasal polyposis, sinusitis, and allergic rhinitis; examination of the neck for masses and tracheal deviation; a complete cardiopulmonary exam, looking for focal versus diffuse wheeze, stridor, situs inversus and evidence of alternative diagnoses (eg, crackles suggestive of hypersensitivity pneumonitis, cryptogenic organizing pneumonitis, interstitial lung disease, or heart failure); and skin examination looking for stigmata of atopic dermatitis, sarcoidosis, and vasculitis.</p><p class="headingAnchor" id="H5"><span class="h2">Trigger identification</span><span class="headingEndMark"> — </span>Ongoing exposures to triggers in any setting may contribute to poor asthma control, so the patient's home, school, and work environments should be carefully reviewed. Triggers may be inhaled (eg, allergens, irritants) or ingested (eg, NSAID and beta blocker medications). A series of potential questions is given in the table  (<a class="graphic graphic_table graphicRef80507" href="/z/d/graphic/80507.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a>.)</p><p>Occupational asthma may not be immediately apparent; patients should be asked about workplace exposures to inhaled allergens, such as laboratory animals, latex, and flour, as well as sensitizers such as glutaraldehyde, toluene diisocyanate, and trimellitic anhydride  (<a class="graphic graphic_table graphicRef66185" href="/z/d/graphic/66185.html" rel="external">table 6</a>). Some of the antigens may cause both asthma and hypersensitivity pneumonitis. (See <a class="local">'Assessing conditions that mimic asthma'</a> below and  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Pulmonary function tests</span><span class="headingEndMark"> — </span>In patients with severe asthma, additional pulmonary function testing beyond spirometry is warranted. The most helpful testing includes pre- and post-bronchodilator spirometry with inspiratory and expiratory flow loops, lung volumes, and diffusing capacity. Confirmation of the asthma diagnosis requires evidence of expiratory airflow limitation with a bronchodilator response. (See  <a class="medical medical_review" href="/z/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/z/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p>Persistent airflow limitation is seen in approximately 50 percent of patients with severe asthma [<a href="#rid17">17</a>]. In addition, air trapping, as manifest by a reduced forced vital capacity (FVC) and increased residual volume and total lung capacity (on plethysmographic pulmonary function testing), is characteristic of severe asthma [<a href="#rid18">18</a>]. In cases where there is a minimal expiratory airflow limitation, often in the face of a high degree of symptoms, a <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge can determine the presence of hyperreactive airways. The diffusing capacity for carbon monoxide (DLCO) is typically normal or increased in asthma. However, some variants of severe asthma, including asthmatic granulomatosis, may have moderate reductions in diffusing capacity. (See  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing"</a> and  <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Lab/immunologic testing</span><span class="headingEndMark"> — </span>There are no laboratory tests that confirm or exclude asthma, but testing can help to evaluate associated conditions and asthma triggers.</p><p>For virtually all patients with severe persistent asthma, a complete blood count (CBC), peripheral blood eosinophil count (to evaluate the presence/absence of eosinophils and exclude anemia as a cause of dyspnea), and a total serum immunoglobulin E (IgE) level (eg, for allergic bronchopulmonary aspergillosis [ABPA] or identification of candidates for anti-IgE therapy) are obtained.</p><p>Specific testing for aspergillus sensitization (skin test or immunoassay) and an antineutrophil cytoplasmic antibody (ANCA) are performed in those with high blood eosinophils to evaluate for ABPA and eosinophilic granulomatosis with polyangiitis (EGPA), respectively. (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p>For the lifelong non-smoker with persistent and irreversible airflow obstruction, a one-time measurement of the serum alpha-1 antitrypsin level is recommended. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a>.)</p><p>If the patient has not had specific allergy testing, either allergy skin tests or immunoassays for allergen-specific IgE should be done if environmental factors are suspected triggers (eg, a cat or dog in the household). (See  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Tests for allergy'</a>.)</p><p>In patients from endemic areas, eosinophilia may be a manifestation of <em>Strongyloides</em> or filarial infection and can be further evaluated with specific antibody testing. In patients born in developed countries, eosinophilia is more likely to be due to adult onset (or aspirin-sensitive) asthma, allergic bronchopulmonary aspergillosis, asthmatic granulomatosis, or rarely, EGPA. However, peripheral eosinophilia can be seen across all subphenotypes of Type-2 asthma. (See <a class="local">'Assessing conditions that mimic asthma'</a> below and  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Phenotyping based on biomarkers of inflammation'</a>.)</p><p>For patients with persistent dyspnea that is not well-explained by the degree of airflow limitation noted on pulmonary function tests, measurement of B-type natriuretic peptide (BNP) with evaluation of cardiac function (eg, echocardiogram) may help to exclude cardiac disease.</p><p class="headingAnchor" id="H8"><span class="h2">Airway inflammation</span><span class="headingEndMark"> — </span>The European Respiratory Society/American Thoracic Society guidelines suggest that treatment of severe asthma be guided by clinical criteria and biomarkers such as blood, sputum eosinophil counts, or fraction of exhaled nitric oxide (FE<sub>NO</sub>), rather than by clinical criteria alone [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Phenotyping based on biomarkers of inflammation'</a> and  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood eosinophil count</strong> – A peripheral blood eosinophil count is an indirect way to estimate airway inflammation. A blood eosinophil count ≥300 cells/microL may help to predict asthmatics who are at increased risk for exacerbations in the next year [<a href="#rid20">20-22</a>]. In addition, the blood eosinophil count is used to identify patients with severe eosinophilic asthma who may benefit from anti-interleukin (IL)-5 or anti-IL-4 receptor alpha antibody therapy, although the precise cut-points for response to these therapies is less clear  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sputum eosinophils and neutrophils</strong> – Sputum analyses must be done by a trained technician to standardize both collection and cell counting and have limited availability. Generally, an induced sputum eosinophil count ≥3 percent is considered elevated [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Phenotyping based on biomarkers of inflammation'</a> and  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p></p><p class="bulletIndent1">The presence of sputum eosinophils despite high dose inhaled or oral glucocorticoids has been associated with more symptomatic disease and worse outcomes [<a href="#rid23">23</a>]. Several studies have evaluated eosinophil counts in induced sputum and on endobronchial biopsies to determine whether persistent eosinophilic or neutrophilic inflammation might be contributing to poor asthma control [<a href="#rid13">13,17,23-26</a>]. In a systematic review of six studies (374 participants with moderate to severe asthma), evaluation and treatment based on sputum eosinophils led to fewer exacerbations than management based on symptoms and/or lung function (OR 0.57, 95% CI 0.38-0.86) [<a href="#rid26">26</a>]. However, no difference was noted in symptoms, quality of life, or lung function.</p><p></p><p class="bulletIndent1">Some patients with severe asthma have elevated sputum neutrophil counts alone or in combination with sputum eosinophilia, raising the possibility that they have an alternate asthma pathogenesis [<a href="#rid11">11,13,24,27-30</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Neutrophilic asthma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fraction of exhaled nitric oxide (FE</strong><strong><sub>NO</sub></strong><strong>)</strong> – The FE<sub>NO</sub> is another method to assess ongoing airway inflammation [<a href="#rid31">31,32</a>]. Sustained high levels of FE<sub>NO</sub> appear to be strongly associated with both regular use of systemic glucocorticoids and increased exacerbation risk in patients with severe asthma [<a href="#rid33">33,34</a>]. Management of patients by monitoring and treatment of FE<sub>NO</sub>, though much easier to collect than sputum, has not been shown to be of clear clinical benefit [<a href="#rid31">31</a>]. However, FE<sub>NO</sub> predicts improvement in FEV<sub>1</sub> in patients treated with some biologics, particularly anti-IL-4Ra antibodies [<a href="#rid35">35,36</a>]. Thus, its utility in severe asthma is evolving. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endobronchial biopsies</strong> – Obtaining endobronchial biopsies to assess eosinophilic inflammation carries greater risk than induced sputum and should only be performed at institutions where quantitative measurements are commonly obtained. Bronchoscopy may be helpful to evaluate interstitial findings on CT scanning, for example when chronic eosinophilic pneumonia, sarcoidosis, or hypersensitivity pneumonitis are suspected. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p></p><p class="headingAnchor" id="H3809258305"><span class="h2">Phenotyping asthma</span><span class="headingEndMark"> — </span>Some experts have suggested that patients with severe asthma can be characterized into phenotypes [<a href="#rid11">11,13,24,27,37</a>]. Briefly, among patients with severe asthma some are atopic and "early onset," some have a course characterized by frequent and often severe exacerbations, and others have chronic, sometimes severe, airflow limitation that is only partially reversible. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a>.)</p><p>One "phenotype" of asthma appears to be predominantly T helper lymphocyte (Th)2-Hi (now termed Type-2 given the broader cell sources for IL-5 and -13 than T-cells alone) with eosinophilic inflammation (eg, innate lymphoid Type 2 cells) [<a href="#rid38">38-40</a>] (see  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'Th2'</a>). It is hypothesized that identification of Type-2 Hi severe asthma may allow more targeted therapy with interventions, such as increased doses of glucocorticoids or <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, which may be less effective in patients without Type-2 inflammation [<a href="#rid41">41</a>]. Type-2-targeted therapies (eg, antibodies to interleukin [IL]-4, IL-5, IL-13) may be more effective in patients with Type-2 inflammation. These therapies are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/526.html" rel="external">"Investigational agents for asthma", section on 'Biologic agents'</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Persistently uncontrolled asthma'</a>.)</p><p>Severe asthma in the absence of evidence for Type-2 inflammation remains poorly understood, although co-morbidities, such as obesity and other metabolic factors, may play important roles [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Chest imaging</span><span class="headingEndMark"> — </span>A chest radiograph can be performed in patients with symptoms suggestive of severe asthma, especially if the symptoms are somewhat atypical, even though this would not be indicated in the routine evaluation of asthma [<a href="#rid2">2</a>]. If interstitial opacities are noted on the chest radiograph or if the diffusing capacity (DLCO) is reduced, a high-resolution CT (HRCT) scan of the thorax should be performed to assess for interstitial lung disease and bronchiolitis. When trying to discriminate between severe asthma and bronchiolitis, the presence of a mosaic attenuation pattern makes bronchiolitis more likely [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a>.)</p><p>HRCT can also be helpful in identifying bronchiectasis, tracheal strictures and masses, and vascular anomalies that mimic asthma (eg, right sided aortic arch and aberrant left subclavian artery) [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/5757.html" rel="external">"Vascular rings and slings"</a>.)</p><p>The European Respiratory Society and the American Thoracic Society (ERS/ATS) severe asthma task force suggests an HRCT when the presentation of the patient is somewhat atypical, such as a rapid decline in lung function, reduced DLCO, or excessive mucus production [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H11"><span class="h1">MEDICATION ADHERENCE</span><span class="headingEndMark"> — </span>Incomplete compliance/adherence to medication is present in many, if not all, chronic diseases and generally to the same degree (approximately 50 percent) [<a href="#rid47">47</a>]. Asthma is no exception, so compliance/adherence to medications must always be addressed [<a href="#rid48">48-50</a>].</p><p>Compliance/adherence should be encouraged in a non-judgmental manner (especially if a medication is known to be helpful to that patient), and reasons behind non-adherence explored (eg, fear of side effects or dependence, forgetfulness, cost of medication). (See  <a class="medical medical_review" href="/z/d/html/556.html" rel="external">"Enhancing patient adherence to asthma therapy"</a>.)</p><p>An overall understanding of the patient's social situation regarding access to medical care, medications and their costs is also important.</p><p>If available, pharmacy records can supplement patient report of adherence. Additionally, in patients on oral glucocorticoids, a fasting morning cortisol of &lt;5 mcg/dL is helpful to measure compliance, as is the presence of steroid side effects.</p><p class="headingAnchor" id="H12"><span class="h1">ASSESSING CONDITIONS THAT MIMIC ASTHMA</span><span class="headingEndMark"> — </span>Several conditions share a symptom complex and can be confused with severe asthma; the most common ones presenting to an asthma specialty clinic are reviewed here  (<a class="graphic graphic_table graphicRef52599" href="/z/d/graphic/52599.html" rel="external">table 8</a>). In addition, some of the conditions that mimic asthma may also accompany asthma including: paradoxical vocal fold motion, allergic bronchopulmonary aspergillosis, chronic obstructive pulmonary disease (COPD), chronic eosinophilic pneumonia, and eosinophilic granulomatosis with polyangiitis (EGPA). These conditions cause the asthma to appear more severe, and require specific treatment separate from asthma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inducible laryngeal obstruction (paradoxical vocal fold motion) </strong>– The most common masquerader of severe asthma is inducible laryngeal obstruction (ILO; also called paradoxical vocal fold motion or vocal cord dysfunction) [<a href="#rid51">51,52</a>]. This syndrome involves involuntary closure of the vocal folds, commonly during inspiration, and can be seen in both men and women. Symptoms include episodic and severe shortness of breath, wheezing, and intractable cough, often in response to irritant exposures (perfumes) or exercise. Patients may have concomitant dysphonia and frequently report an "inability to get enough air (in)." This diagnosis can be made using a combination of inspiratory flow volume loops and laryngoscopy during symptoms, possibly performed at the time of <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> or exercise challenge. (See <a class="local">'Pulmonary function tests'</a> above and  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1">It is important to note that ILO can also occur in the presence of severe asthma. It is often triggered by exercise and worsened by factors that also worsen asthma, including post nasal drip, gastroesophageal reflux disease (GERD), and anxiety [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a> and  <a class="medical medical_review" href="/z/d/html/119345.html" rel="external">"Exercise-induced laryngeal obstruction"</a>.)</p><p></p><p class="bulletIndent1">Vocal fold paralysis and vocal fold lesions are associated with exertional dyspnea and, frequently, dysphonia. A history of intubation, trauma, or surgery with potential injury to the laryngeal nerve would be a clue to evaluate these diagnoses further. (See  <a class="medical medical_review" href="/z/d/html/6851.html" rel="external">"Hoarseness in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central airway obstruction</strong> – Central airway obstruction includes tracheal strictures (eg, from prior intubation), tracheal compression by goiter, tracheal and proximal bronchial tumors, and vascular rings [<a href="#rid44">44</a>]. Patients may present with exertional dyspnea and, sometimes, monophonic wheeze or stridor.</p><p></p><p class="bulletIndent1">A flow volume loop including the inspiratory phase is the first step in evaluation (see <a class="local">'Pulmonary function tests'</a> above). Chest computed tomography (CT) may detect airway compromise, but the test as routinely performed is not sensitive. If an airway lesion is suspected, a high-resolution CT (HRCT) with three-dimensional airway reconstruction can prove helpful, but direct visualization is usually needed for definitive diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic obstructive pulmonary disease </strong>– COPD should be considered in patients with a history of smoking (eg, greater than 15 to 20 pack-years), fume or dust exposure, or a family history of emphysema or alpha-1 antitrypsin deficiency [<a href="#rid54">54</a>]. Some patients may have features of both asthma and COPD, as described separately. (See  <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">"Asthma and COPD overlap (ACO)"</a> and  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Risk factors, including smoking and inhalational exposures'</a>.)</p><p></p><p class="bulletIndent1">In addition to the history of smoking, clues to the presence of COPD include irreversible airflow obstruction and the combination of airflow obstruction and a low diffusing capacity (DLCO). (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchiectasis</strong> – Patients with bronchiectasis typically have a chief complaint of productive cough, and the amount of sputum production is usually more than what would be expected in pure asthma. An end-inspiratory squeak may be heard on physical exam that can mimic a wheeze. The cough is typically refractory to bronchodilator therapy. HRCT of the thorax will help determine whether bronchiectasis is present. (See  <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic bronchopulmonary aspergillosis</strong> (ABPA) may develop in patients with asthma due to colonization of the airways with aspergillus and typically presents with recurrent mucoid impaction and atelectasis. The resulting immunologic reaction leads to proximal bronchiectasis. ABPA should be suspected in patients who have skin test positivity to aspergillus and elevated IgE levels (&gt;1000 ng/mL). (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchiolitis</strong> – Several bronchiolar diseases share features of asthma, such as cough and dyspnea that worsens with exertion. Bronchiolitis is typically a consequence of a respiratory infection, inhalational injury, organ transplantation, or connective tissue disease. Physical exam may reveal crackles and inspiratory squeaks; pulmonary function tests show progressive airflow obstruction not responsive to bronchodilator; DLCO and oxygen saturation are reduced; and chest CT scan will show interstitial opacities in a mosaic pattern [<a href="#rid43">43</a>]. Inspiratory and expiratory views on HRCT may reveal patchy areas of air trapping. (See  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilic obliterative bronchiolitis</strong> – A small number of patients with clinical features of severe asthma have been found to have hypereosinophilic obliterative bronchiolitis [<a href="#rid55">55-57</a>]. Differentiating characteristics of this condition include a peripheral blood eosinophil count ≥1000 cells/microL (1 x 10<sup>9</sup>/L) and/or bronchoalveolar lavage eosinophils &gt;25 percent; persistent airflow obstruction with a post bronchodilator FEV<sub>1</sub> &lt;80 percent predicted and an FEV<sub>1</sub>/FVC &lt;70 percent not improved after four to six weeks of high dose inhaled glucocorticoids; and a lung biopsy showing prominent bronchiolar wall infiltration by eosinophils and/or HRCT features of bronchiolitis. Hypereosinophilic obliterative bronchiolitis appears to respond to oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> with initial doses of 0.5 to 1 mg/kg per day tapering to maintenance doses of approximately 10 mg per day [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryptogenic organizing pneumonia</strong> – Cryptogenic organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP) is usually manifest by a nonproductive cough, sometimes dyspnea, systemic symptoms of malaise, and sometimes fever. Crackles are usually noted on chest exam and an HRCT reveals interstitial opacities and/or patchy areas of consolidation. Pulmonary function tests typically show a restrictive pattern; airflow limitation is seen uncommonly and generally only in cigarette smokers. Usually, a lung biopsy is required for diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis</strong> – Patients with hypersensitivity pneumonitis (HP) may report intermittent dyspnea than can be confused with asthma. Exposure to allergens that typically cause HP (eg, birds, barns, humidifiers) should alert the clinician to this possibility. Pulmonary function tests may show a mixed obstructive and restrictive pattern and a reduced DLCO. Fleeting infiltrates are another clue. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilia and respiratory symptoms</strong> – Filarial and strongyloides infections and EGPA may present with asthma that cannot be controlled until the underlying disease is treated. Filarial and strongyloides infection should be suspected in patients from an endemic area, who have blood eosinophilia and an elevated IgE level. Specific IgG antibodies to filarial and strongyloides antigens will be positive. Improvement with specific treatment confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.)</p><p></p><p class="bulletIndent1">Patients with EGPA and chronic eosinophilic pneumonia (CEP) may have asthma, but also have other findings (eg, blood eosinophilia, pulmonary infiltrates). Paranasal sinus disease, skin lesions, a peripheral neuropathy, and eosinophilia &gt;10 percent are common in EGPA, although blood eosinophilia may be masked by systemic glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a> and  <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1">Concomitant fever, weight loss, and night sweats are often seen in CEP; blood eosinophilia may be absent. (See  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia", section on 'Chronic eosinophilic pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthmatic granulomatosis</strong> – Among patients with severe asthma, a subset has been described with nonnecrotizing granulomas in the lung interstitium, asthma-like submucosal inflammation, and mucus plugging in the small airways, but without clinical evidence of hypersensitivity pneumonitis or pathologic evidence of vasculitis [<a href="#rid58">58</a>]. This disease process has been called "asthmatic granulomatosis." Affected patients frequently have eosinophilia and chronic rhinosinusitis (with or without nasal polyposis) and may have a reduced diffusing capacity. Chest CT may be normal or show air trapping, mosaicism, bronchial dilatation, or bronchial wall thickening. There is often a strong family or personal history of autoimmune disease. The optimal evaluation and management of these patients have not been defined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcoidosis</strong> – Endobronchial sarcoidosis can present with a refractory cough and dyspnea. Chest radiograph and CT will likely show typical findings of hilar adenopathy and reticular or nodular opacities. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac disease</strong> – Heart failure can mimic asthma in older adults and can be evaluated with B-type natriuretic peptide (BNP), chest radiograph, and echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/521.html" rel="external">"Diagnosis and management of asthma in older adults", section on 'Heart failure versus asthma'</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">ASSESSING COMORBID CONDITIONS</span><span class="headingEndMark"> — </span>A number of comorbid diseases can contribute to the severity of asthma and should be evaluated in patients with severe asthma  (<a class="graphic graphic_table graphicRef61331" href="/z/d/graphic/61331.html" rel="external">table 9</a>). Addressing these issues may reduce asthma symptoms in some patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic rhinosinusitis</strong> – Chronic rhinosinusitis is a frequent comorbid condition and is an independent risk factor for exacerbations of asthma [<a href="#rid59">59</a>]. At least some studies in milder asthma suggest that improved upper airway therapy leads to better asthma outcomes [<a href="#rid60">60,61</a>].</p><p></p><p class="bulletIndent1">Allergic rhinitis symptoms and signs should be evaluated and the nose examined for nasal polyps. Patients with nasal polyposis and asthma are likely to have aspirin-exacerbated respiratory disease (AERD) and to have sudden and life-threatening flares of asthma after ingestion of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or NSAIDs. Even in the absence of aspirin or NSAID ingestion, they are likely to have severe asthma symptoms. (See  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a>.)</p><p></p><p class="bulletIndent1">In patients with severe asthma, at least one sinus computed tomography (CT) scan looking for chronic rhinosinusitis is probably appropriate, although studies to demonstrate the cost efficacy of this test are not available. Multiplanar sinus CT scan is the preferred imaging modality when evaluating for comorbid chronic rhinosinusitis. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Sinus CT'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux</strong> – Gastroesophageal reflux disease (GERD) is commonly seen in association with severe asthma, but whether treatment improves asthma remains controversial. (See  <a class="medical medical_review" href="/z/d/html/571.html" rel="external">"Gastroesophageal reflux and asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – Several studies report that asthmatics who smoke are at increased risk for exacerbations, have impaired lung function, and respond poorly to inhaled glucocorticoids [<a href="#rid62">62,63</a>]. Every effort should be made for the patient to quit; patients should also understand that ongoing smoking is a risk factor for fatal asthma. (See  <a class="medical medical_patient" href="/z/d/html/2729.html" rel="external">"Patient education: Quitting smoking (Beyond the Basics)"</a> and  <a class="medical medical_review" href="/z/d/html/565.html" rel="external">"Identifying patients at risk for fatal asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Obesity (body mass index ≥30 kg/m<sup>2</sup>) is common in patients with severe asthma. Obesity has been associated with increased incident asthma in women and with worsened asthma severity [<a href="#rid64">64-66</a>]. Unfortunately, weight loss is difficult for patients with severe asthma, particularly when they require systemic glucocorticoids; in addition to the effects of glucocorticoids, activity is often limited by dyspnea. (See  <a class="medical medical_review" href="/z/d/html/119911.html" rel="external">"Obesity and asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructive sleep apnea</strong> – Obstructive sleep apnea (OSA) is a common disorder that may occur together with asthma and shares certain predisposing factors [<a href="#rid67">67-69</a>]. Both obesity and nasal congestion (eg, from allergic rhinitis or nasal polyposis) may further contribute to the development of OSA [<a href="#rid59">59,70,71</a>]. Daytime sleepiness in patients with asthma is more likely related to OSA than asthma [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">Polysomnography is suggested in patients with symptoms and clinical features suggestive of OSA, particularly when nocturnal symptoms are persistent. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychiatric disorders</strong> – Psychiatric disorders have long been associated with severe asthma [<a href="#rid72">72-78</a>]. In one study, anxiety and depression were present to a much greater degree in patients with severe asthma than the normal population and were a risk factor for more severe asthma [<a href="#rid73">73</a>]. However, it is not clear whether the anxiety and depression are truly risk factors for severe asthma or the result of severe asthma.</p><p></p><p class="headingAnchor" id="H258343248"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112676.html" rel="external">"Society guideline links: Severe asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/371.html" rel="external">"Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/373.html" rel="external">"Patient education: Trigger avoidance in asthma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe asthma are typically in the "severe persistent asthma" and "very poorly controlled" categories of the NHLBI and Global Initiative for Asthma (GINA) guidelines. A consensus definition of severe asthma requires that patients have needed therapy with high dose inhaled glucocorticoid  (<a class="graphic graphic_table graphicRef78011" href="/z/d/graphic/78011.html" rel="external">table 1</a>) and a long-acting beta-agonist (LABA) or leukotriene modifier/<a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> for the previous year and/or have needed systemic glucocorticoids for 50 percent or more of the year to prevent asthma from becoming uncontrolled; other conditions must have been excluded, and exacerbating factors treated  (<a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">table 2</a>). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Important elements in the history include: age of onset of symptoms, exact description of symptoms, temporal pattern of symptoms, exacerbating factors  (<a class="graphic graphic_table graphicRef80507" href="/z/d/graphic/80507.html" rel="external">table 5</a>), and family history of atopic disease. Assessment of the frequency and severity of asthma exacerbations helps to predict the risk of future exacerbations. (See <a class="local">'History and physical'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typical masqueraders of severe asthma include (in general order of likelihood): inducible laryngeal obstruction (vocal cord dysfunction), chronic obstructive pulmonary disease (COPD), bronchiectasis, hypersensitivity pneumonitis (HP), hypereosinophilic syndromes (including eosinophilic granulomatosis with polyangiitis), constrictive bronchiolitis, and endobronchial sarcoidosis  (<a class="graphic graphic_table graphicRef52599" href="/z/d/graphic/52599.html" rel="external">table 8</a>). (See <a class="local">'Assessing conditions that mimic asthma'</a> above and  <a class="medical medical_review" href="/z/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suggested pulmonary function tests include spirometry pre- and post-bronchodilator with inspiratory and expiratory flow loops, lung volumes, and diffusing capacity. Confirmation of the asthma diagnosis requires expiratory airflow limitation with a bronchodilator response or a positive <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge. (See <a class="local">'Pulmonary function tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing in asthma is rarely diagnostic, but certain tests may be helpful, including CBC and blood eosinophil count, total IgE level, alpha-1 antitrypsin, and ANCA. Specific allergen skin testing or immunoassays for allergen-specific IgE may help identify triggers like dust mites and animal dander. (See <a class="local">'Lab/immunologic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph and CT scans may help identify diseases that mimic asthma like central airway obstruction, bronchiectasis, bronchiolitis and vascular rings. (See <a class="local">'Chest imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication adherence is an important cause of poorly controlled asthma, especially when more complicated treatment regimens become necessary. (See <a class="local">'Medication adherence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid conditions like rhinosinusitis and obesity appear to exacerbate asthma  (<a class="graphic graphic_table graphicRef61331" href="/z/d/graphic/61331.html" rel="external">table 9</a>). It is controversial whether gastroesophageal reflux disease (GERD) exacerbates asthma, but is common among patients with asthma. Obstructive sleep apnea may contribute to nocturnal respiratory symptoms. (See <a class="local">'Assessing comorbid conditions'</a> above.)</p><p></p><p>The treatment of severe asthma in adolescents and adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23:723.</a></li><li><a class="nounderline abstract_t">Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed February 12, 2008).</li><li><a class="nounderline abstract_t">Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135:896.</a></li><li><a class="nounderline abstract_t">Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133:1280.</a></li><li><a class="nounderline abstract_t">Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315.</a></li><li><a class="nounderline abstract_t">Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218.</a></li><li><a class="nounderline abstract_t">Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405.</a></li><li><a class="nounderline abstract_t">Dixon AE, Yeh F, Welty TK, et al. Asthma in American Indian adults: the Strong Heart Study. Chest 2007; 131:1323.</a></li><li><a class="nounderline abstract_t">Eisner MD, Yelin EH, Katz PP, et al. Risk factors for work disability in severe adult asthma. Am J Med 2006; 119:884.</a></li><li><a class="nounderline abstract_t">The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470.</a></li><li><a class="nounderline abstract_t">Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910.</a></li><li><a class="nounderline abstract_t">Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101.</a></li><li><a class="nounderline abstract_t">Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Rao CK, Moore CG, Bleecker E, et al. Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program. Chest 2013; 143:984.</a></li><li><a class="nounderline abstract_t">Martinez-Moragón E, Plaza V, Serrano J, et al. Near-fatal asthma related to menstruation. J Allergy Clin Immunol 2004; 113:242.</a></li><li><a class="nounderline abstract_t">ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744.</a></li><li><a class="nounderline abstract_t">Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) 2008; 104:394.</a></li><li><a class="nounderline abstract_t">Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Zeiger RS, Schatz M, Dalal AA, et al. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study. J Allergy Clin Immunol Pract 2017; 5:144.</a></li><li><a class="nounderline abstract_t">Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3:849.</a></li><li><a class="nounderline abstract_t">Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med 2018; 378:2486.</a></li><li><a class="nounderline abstract_t">Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715.</a></li><li><a class="nounderline abstract_t">Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001.</a></li><li><a class="nounderline abstract_t">Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483.</a></li><li><a class="nounderline abstract_t">Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2017; 8:CD005603.</a></li><li><a class="nounderline abstract_t">Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7:43.</a></li><li><a class="nounderline abstract_t">Lee JH, Haselkorn T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132:1882.</a></li><li><a class="nounderline abstract_t">Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420.</a></li><li><a class="nounderline abstract_t">Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133:1557.</a></li><li><a class="nounderline abstract_t">Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163.</a></li><li><a class="nounderline abstract_t">Tseliou E, Bessa V, Hillas G, et al. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 2010; 138:107.</a></li><li><a class="nounderline abstract_t">Wysocki K, Park SY, Bleecker E, et al. Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program. J Allergy Clin Immunol 2014; 133:915.</a></li><li><a class="nounderline abstract_t">Bal C, Idzko M, Škrgat S, et al. Fraction of exhaled nitric oxide is associated with disease burden in the German Asthma Net severe asthma cohort. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455.</a></li><li><a class="nounderline abstract_t">Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388:31.</a></li><li><a class="nounderline abstract_t">Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013; 132:336.</a></li><li><a class="nounderline abstract_t">Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388.</a></li><li><a class="nounderline abstract_t">McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612.</a></li><li><a class="nounderline abstract_t">Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651.</a></li><li><a class="nounderline abstract_t">Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804.</a></li><li><a class="nounderline abstract_t">Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol 2015; 308:L130.</a></li><li><a class="nounderline abstract_t">Jensen SP, Lynch DA, Brown KK, et al. High-resolution CT features of severe asthma and bronchiolitis obliterans. Clin Radiol 2002; 57:1078.</a></li><li><a class="nounderline abstract_t">Morel V, Corbineau H, Lecoz A, et al. Two cases of 'asthma' revealing a diverticulum of Kommerell. Respiration 2002; 69:456.</a></li><li><a class="nounderline abstract_t">Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136:1521.</a></li><li><a class="nounderline abstract_t">Fritscher LG, Marras TK, Bradi AC, et al. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest 2011; 139:23.</a></li><li><a class="nounderline abstract_t">Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17:205.</a></li><li><a class="nounderline abstract_t">Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109:S554.</a></li><li><a class="nounderline abstract_t">Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180:817.</a></li><li><a class="nounderline abstract_t">Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128:1185.</a></li><li><a class="nounderline abstract_t">Thomas PS, Geddes DM, Barnes PJ. Pseudo-steroid resistant asthma. Thorax 1999; 54:352.</a></li><li><a class="nounderline abstract_t">Low K, Lau KK, Holmes P, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med 2011; 184:50.</a></li><li><a class="nounderline abstract_t">Balkissoon R. Vocal cord dysfunction, gastroesophageal reflux disease, and nonallergic rhinitis. Clin Allergy Immunol 2007; 19:411.</a></li><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Cordier JF, Cottin V, Khouatra C, et al. Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome. Eur Respir J 2013; 41:1126.</a></li><li><a class="nounderline abstract_t">Takayanagi N, Kanazawa M, Kawabata Y, Colby TV. Chronic bronchiolitis with associated eosinophilic lung disease (eosinophilic bronchiolitis). Respiration 2001; 68:319.</a></li><li><a class="nounderline abstract_t">Fukushima Y, Kamiya K, Tatewaki M, et al. A patient with bronchial asthma in whom eosinophilic bronchitis and bronchiolitis developed during treatment. Allergol Int 2010; 59:87.</a></li><li><a class="nounderline abstract_t">Wenzel SE, Vitari CA, Shende M, et al. Asthmatic granulomatosis: a novel disease with asthmatic and granulomatous features. Am J Respir Crit Care Med 2012; 186:501.</a></li><li><a class="nounderline abstract_t">ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812.</a></li><li><a class="nounderline abstract_t">Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250.</a></li><li><a class="nounderline abstract_t">Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:636.</a></li><li><a class="nounderline abstract_t">Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24:822.</a></li><li><a class="nounderline abstract_t">Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007; 120:1036.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Plaza V. Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study. Chest 2007; 132:1513.</a></li><li><a class="nounderline abstract_t">Mosen DM, Schatz M, Magid DJ, Camargo CA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008; 122:507.</a></li><li><a class="nounderline abstract_t">Devouassoux G, Lévy P, Rossini E, et al. Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 2007; 119:597.</a></li><li><a class="nounderline abstract_t">Bonekat HW, Hardin KA. Severe upper airway obstruction during sleep. Clin Rev Allergy Immunol 2003; 25:191.</a></li><li><a class="nounderline abstract_t">Teodorescu M, Polomis DA, Hall SV, et al. Association of obstructive sleep apnea risk with asthma control in adults. Chest 2010; 138:543.</a></li><li><a class="nounderline abstract_t">Teodorescu M, Consens FB, Bria WF, et al. Correlates of daytime sleepiness in patients with asthma. Sleep Med 2006; 7:607.</a></li><li><a class="nounderline abstract_t">Yigla M, Tov N, Solomonov A, et al. Difficult-to-control asthma and obstructive sleep apnea. J Asthma 2003; 40:865.</a></li><li><a class="nounderline abstract_t">ten Brinke A, Ouwerkerk ME, Bel EH, Spinhoven P. Similar psychological characteristics in mild and severe asthma. J Psychosom Res 2001; 50:7.</a></li><li><a class="nounderline abstract_t">Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000; 30:319.</a></li><li><a class="nounderline abstract_t">Mancuso CA, Wenderoth S, Westermann H, et al. Patient-reported and physician-reported depressive conditions in relation to asthma severity and control. Chest 2008; 133:1142.</a></li><li><a class="nounderline abstract_t">Goldney RD, Ruffin R, Fisher LJ, Wilson DH. Asthma symptoms associated with depression and lower quality of life: a population survey. Med J Aust 2003; 178:437.</a></li><li><a class="nounderline abstract_t">Lavoie KL, Bouthillier D, Bacon SL, et al. Psychologic distress and maladaptive coping styles in patients with severe vs moderate asthma. Chest 2010; 137:1324.</a></li><li><a class="nounderline abstract_t">Amelink M, Hashimoto S, Spinhoven P, et al. Anxiety, depression and personality traits in severe, prednisone-dependent asthma. Respir Med 2014; 108:438.</a></li><li><a class="nounderline abstract_t">Han YY, Forno E, Marsland AL, et al. Depression, Asthma, and Bronchodilator Response in a Nationwide Study of US Adults. J Allergy Clin Immunol Pract 2016; 4:68.</a></li></ol></div><div id="topicVersionRevision">Topic 564 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15176687" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Asthma severity and medical resource utilisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337046" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337046" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441637" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The prevalence of severe refractory asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24589344" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892860" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480428" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cluster analysis and clinical asthma phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291857" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17400687" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Asthma in American Indian adults: the Strong Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000221" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for work disability in severe adult asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516137" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713914" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139780" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632943" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767436" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Near-fatal asthma related to menstruation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549526" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Factors associated with persistent airflow limitation in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991792" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558662" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665383" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493938" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29782217" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471631" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507847" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28837221" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218810" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The reclassification of asthma based on subphenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079222" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071017" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Differences in airway cytokine profile in severe asthma compared to moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332216" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914548" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of exhaled nitric oxide measurements to guide treatment in chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173051" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332222" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35273030" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fraction of exhaled nitric oxide is associated with disease burden in the German Asthma Net severe asthma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688323" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dupilumab in persistent asthma with elevated eosinophil levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27130691" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-actingβ2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806634" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Severe adult-onset asthma: A distinct phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483109" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : T-helper type 2-driven inflammation defines major subphenotypes of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268133" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A large subgroup of mild-to-moderate asthma is persistently noneosinophilic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901886" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23471469" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326577" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Emerging molecular phenotypes of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475532" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High-resolution CT features of severe asthma and bronchiolitis obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12232456" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Two cases of 'asthma' revealing a diverticulum of Kommerell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542254" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Qualitative analysis of high-resolution CT scans in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829338" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239231" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063512" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Overcoming barriers to nonadherence in asthma treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644048" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The prevalence of nonadherence in difficult asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019090" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092698" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pseudo-steroid resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471099" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Abnormal vocal cord function in difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153031" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Vocal cord dysfunction, gastroesophageal reflux disease, and nonallergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153031" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vocal cord dysfunction, gastroesophageal reflux disease, and nonallergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23258778" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416256" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Chronic bronchiolitis with associated eosinophilic lung disease (eosinophilic bronchiolitis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19946200" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A patient with bronchial asthma in whom eosinophilic bronchitis and bronchiolitis developed during treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22773731" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Asthmatic granulomatosis: a novel disease with asthmatic and granulomatous features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264041" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk factors of frequent exacerbations in difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1500629" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intranasal steroids and the risk of emergency department visits for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516679" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Asthma and cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935765" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573048" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prospective study of body mass index, weight change, and risk of adult-onset asthma in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17890469" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18774387" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The relationship between obesity and asthma severity and control in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261329" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573885" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Severe upper airway obstruction during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495105" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Association of obstructive sleep apnea risk with asthma control in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815750" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Correlates of daytime sleepiness in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736085" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Difficult-to-control asthma and obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11259794" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Similar psychological characteristics in mild and severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11308036" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Psychiatric diagnoses in inner city outpatients with moderate to severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263683" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Patient-reported and physician-reported depressive conditions in relation to asthma severity and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12720509" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Asthma symptoms associated with depression and lower quality of life: a population survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097803" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Psychologic distress and maladaptive coping styles in patients with severe vs moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462260" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Anxiety, depression and personality traits in severe, prednisone-dependent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563676" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Depression, Asthma, and Bronchodilator Response in a Nationwide Study of US Adults.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
